Gland Pharma Receives USFDA Approval for Vasopressin Injection скачать в хорошем качестве

Gland Pharma Receives USFDA Approval for Vasopressin Injection

Link to our Twitter Profile - https://x.com/intent/user?screen_name... Link to our Telegram Channel - https://t.me/niftybn Link to our Instagram Handle -   / niftybn_   Link to our Facebook Page - https://fb.com/niftybn Gland Pharma Gets USFDA Nod for Vasopressin Injection 💉🌍 | $45M US Market Opportunity 📅 August 26, 2025 Gland Pharma has received USFDA approval for its Vasopressin in 5% Dextrose Injection, a critical treatment for adults with vasodilatory shock who remain hypotensive. ✅ The company has secured full approval for 40 Units/100 mL vials and tentative approval for 20 Units/100 mL vials. 📈 This product targets the US market valued at approximately $45 million (12 months ending June 2025), opening up strong growth opportunities for Gland’s injectable portfolio. ⚡ The approval strengthens Gland Pharma’s positioning as a global generic injectable leader, focused on expanding its presence in key regulated markets. 📌 Key Highlights: ✔️ Product: Vasopressin in 5% Dextrose Injection ✔️ USFDA Approval: 40 Units vial (full) | 20 Units vial (tentative) ✔️ Indication: Vasodilatory shock → increase blood pressure ✔️ US Market Size: ~$45M (as of June 2025) ✔️ Reinforces Gland’s injectable-focused growth strategy #GlandPharma #USFDAApproval #Vasopressin #GenericInjectables #USMarket #PharmaNews #Biopharma #PharmaceuticalsIndia #DrugApproval #HealthcareInnovation #LifeSavingDrugs #PharmaUpdates #CriticalCare #BusinessNews #CorporateUpdates #InvestorUpdate #MedicalAdvances #GlobalPharma #DrugMarkets #IndiaPharma